Ost-müük Enanta - ENTA CFD
Lisa lemmikuks- Kokkuvõte
- Ajaloolised andmed
- Sündmused
- Tuluaruanne
- Bilanss
- Rahavood
- Omand
Hinnavahe | - | ||||||||
Pika positsiooni ööpäeva tasu
Long position overnight fee
Mine platvormile | -0.025457% | ||||||||
Lühikese positsiooni ööpäeva tasu
Short position overnight fee
Mine platvormile | 0.003235% | ||||||||
Ööpäeva tasu aeg | 21:00 (UTC) | ||||||||
Min kauplemise kogus | 1 | ||||||||
Valuuta | USD | ||||||||
Tagatis | 20% | ||||||||
Aktsiabörs | United States of America | ||||||||
Kauplemise vahendustasu | 0% |
*Information provided by Capital.com
Enanta Pharmaceuticals Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Eelmine sulgemine* | N/A |
Avatud* | N/A |
Aastane muutus* | N/A |
Päeva ulatus* | N/A |
52 nädala ulatus | 22.80-76.36 |
Keskmine maht (10 päeva) | 225.85K |
Keskmine maht (3 kuud) | 4.21M |
Turukapitalisatsioon | 494.38M |
P/E suhtarv | -100.00K |
Ringluses olevad aktsiad | 21.06M |
Tulu | 81.18M |
EPS | -5.98 |
Dividendid (% kasumist) | N/A |
Beeta | 0.38 |
Järgmine tuluaruande kuupäev | Aug 7, 2023 |
Kõigi andmete allikas on Refinitiv, välja arvatud tärniga märgitud, kus *-ga andmed on esitanud Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Sulgemishind | Change (%) | Avamishind | High | Low |
---|
Enanta Events
Kellaaeg (UTC) (UTC) | Riik | Sündmus |
---|---|---|
Wednesday, June 7, 2023 | ||
Kellaaeg (UTC) (UTC) 16:30 | Riik US
| Sündmus Enanta Pharmaceuticals Inc at Jefferies Healthcare Conference Enanta Pharmaceuticals Inc at Jefferies Healthcare ConferenceForecast -Previous - |
Monday, August 7, 2023 | ||
Kellaaeg (UTC) (UTC) 10:59 | Riik US
| Sündmus Q3 2023 Enanta Pharmaceuticals Inc Earnings Call Q3 2023 Enanta Pharmaceuticals Inc Earnings CallForecast -Previous - |
Kellaaeg (UTC) (UTC) 10:59 | Riik US
| Sündmus Q3 2023 Enanta Pharmaceuticals Inc Earnings Release Q3 2023 Enanta Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
Monday, November 20, 2023 | ||
Kellaaeg (UTC) (UTC) 10:59 | Riik US
| Sündmus Q4 2023 Enanta Pharmaceuticals Inc Earnings Release Q4 2023 Enanta Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
- Aastas
- Kvartalis
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Kogutulu | 86.16 | 97.074 | 122.473 | 205.197 | 206.625 |
Tulu | 86.16 | 97.074 | 122.473 | 205.197 | 206.625 |
Kogu tegevuskulu | 210.004 | 206.647 | 164.112 | 168.459 | 118.297 |
Müük/Üldine/admin kulud, kokku | 45.482 | 32.536 | 27.356 | 26.246 | 23.441 |
Uuringud ja arendus | 164.522 | 174.111 | 136.756 | 142.213 | 94.856 |
Tulud majandustegevusest | -123.844 | -109.573 | -41.639 | 36.738 | 88.328 |
Intressitulud (kulu), muud tulud, neto | 1.656 | 1.994 | 6.62 | 8.819 | 4.793 |
Netotulu enne makse | -122.188 | -107.579 | -35.019 | 45.557 | 93.121 |
Netotulu pärast makse | -121.755 | -78.996 | -36.168 | 46.383 | 75.756 |
Netotulu enne erikulusid | -121.755 | -78.996 | -36.168 | 46.383 | 75.756 |
Netotulu | -121.755 | -78.996 | -36.168 | 46.383 | 71.956 |
Arvestatav tulu, v a erikulud | -121.755 | -78.996 | -36.168 | 46.383 | 75.756 |
Arvestatav tulu, koos erikuludega | -121.755 | -78.996 | -36.168 | 46.383 | 71.956 |
Jaotamisele kuuluv netotulu | -121.755 | -78.996 | -36.168 | 46.383 | 71.956 |
Keskmine jaotamisele kuuluv aktsia kohta | 20.603 | 20.171 | 19.94 | 20.968 | 20.65 |
Jaotatav EPS, v a erakorralised kulud | -5.90958 | -3.91632 | -1.81384 | 2.21209 | 3.66857 |
Dividends per Share - Common Stock Primary Issue | |||||
Jaotamisele kuuluv normaal-EPS | -5.90958 | -3.91632 | -1.81384 | 2.21209 | 3.66857 |
Erakorralised kulud kokku | -3.8 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Kogutulu | 17.795 | 23.585 | 20.317 | 19.479 | 18.716 |
Tulu | 17.795 | 23.585 | 20.317 | 19.479 | 18.716 |
Kogu tegevuskulu | 57.246 | 53.598 | 47.365 | 52.019 | 52.563 |
Müük/Üldine/admin kulud, kokku | 13.778 | 12.696 | 12.569 | 12.929 | 10.476 |
Uuringud ja arendus | 43.468 | 40.902 | 34.796 | 39.09 | 42.087 |
Tulud majandustegevusest | -39.451 | -30.013 | -27.048 | -32.54 | -33.847 |
Intressitulud (kulu), muud tulud, neto | 1.837 | 0.993 | 0.714 | 0.393 | 0.255 |
Netotulu enne makse | -37.614 | -29.02 | -26.334 | -32.147 | -33.592 |
Netotulu pärast makse | -37.658 | -28.986 | -26.348 | -31.7 | -33.592 |
Netotulu enne erikulusid | -37.658 | -28.986 | -26.348 | -31.7 | -33.592 |
Netotulu | -37.658 | -28.986 | -26.348 | -31.7 | -33.592 |
Arvestatav tulu, v a erikulud | -37.658 | -28.986 | -26.348 | -31.7 | -33.592 |
Arvestatav tulu, koos erikuludega | -37.658 | -28.986 | -26.348 | -31.7 | -33.592 |
Jaotamisele kuuluv netotulu | -37.658 | -28.986 | -26.348 | -31.7 | -33.592 |
Keskmine jaotamisele kuuluv aktsia kohta | 21.035 | 20.816 | 20.756 | 20.71 | 20.551 |
Jaotatav EPS, v a erakorralised kulud | -1.79025 | -1.39249 | -1.26942 | -1.53066 | -1.63457 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Jaotamisele kuuluv normaal-EPS | -1.79025 | -1.39249 | -1.26942 | -1.53066 | -1.63457 |
- Aastas
- Kvartalis
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Käibevarad kokku | 311.713 | 319.021 | 436.837 | 401.848 | 380.389 |
Raha ja lühiajalised investeeringud | 249.232 | 244.002 | 386.649 | 335.236 | 308.73 |
Raha ja ekvivalendid | 43.994 | 57.206 | 87.131 | 51.23 | 63.902 |
Lühiajalised investeeringud | 205.238 | 186.796 | 299.518 | 284.006 | 244.828 |
Laekumata arved, neto | 49.036 | 60.831 | 23.492 | 51.313 | 67.205 |
Accounts Receivable - Trade, Net | 20.318 | 23.576 | 23.492 | 51.313 | 67.205 |
Prepaid Expenses | 13.445 | 14.188 | 26.696 | 15.299 | 4.454 |
Other Current Assets, Total | |||||
Total Assets | 375.41 | 438.791 | 486.132 | 489.829 | 414.227 |
Property/Plant/Equipment, Total - Net | 29.748 | 10.654 | 15.616 | 10.927 | 8.374 |
Property/Plant/Equipment, Total - Gross | 51.606 | 29.58 | 31.29 | 23.108 | 17.466 |
Accumulated Depreciation, Total | -21.858 | -18.926 | -15.674 | -12.181 | -9.092 |
Long Term Investments | 29.285 | 108.416 | 32.634 | 65.013 | 16.389 |
Other Long Term Assets, Total | 4.664 | 0.7 | 1.045 | 12.041 | 9.075 |
Total Current Liabilities | 29.827 | 36.172 | 24.157 | 22.609 | 16.025 |
Accounts Payable | 6 | 9.54 | 5.737 | 6.689 | 4.745 |
Accrued Expenses | 23.827 | 26.632 | 18.42 | 15.92 | 9.892 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | |||||
Other Current Liabilities, Total | 0 | 1.388 | |||
Total Liabilities | 54.076 | 39.362 | 30.552 | 27.337 | 20.548 |
Total Long Term Debt | 1.423 | 1.506 | 1.479 | 1.828 | 1.921 |
Long Term Debt | 1.423 | 1.506 | 1.479 | 1.628 | 1.628 |
Capital Lease Obligations | 0 | 0 | 0.2 | 0.293 | |
Other Liabilities, Total | 22.826 | 1.684 | 4.916 | 2.9 | 2.602 |
Total Equity | 321.334 | 399.429 | 455.58 | 462.492 | 393.679 |
Common Stock | 0.208 | 0.202 | 0.201 | 0.197 | 0.194 |
Additional Paid-In Capital | 398.029 | 351.033 | 326.963 | 298.409 | 276.526 |
Retained Earnings (Accumulated Deficit) | -73.179 | 48.576 | 127.572 | 163.74 | 117.357 |
Other Equity, Total | -3.724 | -0.382 | 0.844 | 0.146 | -0.398 |
Total Liabilities & Shareholders’ Equity | 375.41 | 438.791 | 486.132 | 489.829 | 414.227 |
Total Common Shares Outstanding | 20.791 | 20.238 | 20.077 | 19.703 | 19.395 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Käibevarad kokku | 271.137 | 283.704 | 311.713 | 313.035 | 341.869 |
Raha ja lühiajalised investeeringud | 210.084 | 214.47 | 249.232 | 253.288 | 280.327 |
Raha ja ekvivalendid | 73.178 | 42.223 | 43.994 | 28.367 | 40.989 |
Lühiajalised investeeringud | 136.906 | 172.247 | 205.238 | 224.921 | 239.338 |
Laekumata arved, neto | 46.569 | 51.288 | 49.036 | 48.207 | 47.464 |
Accounts Receivable - Trade, Net | 17.795 | 22.585 | 20.318 | 19.479 | 18.716 |
Prepaid Expenses | 14.484 | 17.946 | 13.445 | 11.54 | 14.078 |
Total Assets | 326.445 | 347.534 | 375.41 | 385.214 | 406.818 |
Property/Plant/Equipment, Total - Net | 35.604 | 32.222 | 29.748 | 28.081 | 22.031 |
Long Term Investments | 15.04 | 26.939 | 29.285 | 39.427 | 42.218 |
Other Long Term Assets, Total | 4.664 | 4.669 | 4.664 | 4.671 | 0.7 |
Total Current Liabilities | 32.166 | 23.001 | 29.827 | 23.035 | 30.738 |
Accounts Payable | 11.761 | 4.352 | 6 | 1.245 | 5.985 |
Accrued Expenses | 20.405 | 18.649 | 23.827 | 21.79 | 24.753 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 57.07 | 46.697 | 54.076 | 47.191 | 48.235 |
Total Long Term Debt | 1.423 | 1.423 | 1.423 | 1.506 | 1.506 |
Long Term Debt | 1.423 | 1.423 | 1.423 | 1.506 | 1.506 |
Other Liabilities, Total | 23.481 | 22.273 | 22.826 | 22.65 | 15.991 |
Total Equity | 269.375 | 300.837 | 321.334 | 338.023 | 358.583 |
Common Stock | 0.21 | 0.209 | 0.208 | 0.207 | 0.206 |
Additional Paid-In Capital | 410.803 | 405.468 | 398.029 | 388.267 | 376.545 |
Retained Earnings (Accumulated Deficit) | -139.823 | -102.165 | -73.179 | -46.831 | -15.131 |
Other Equity, Total | -1.815 | -2.675 | -3.724 | -3.62 | -3.037 |
Total Liabilities & Shareholders’ Equity | 326.445 | 347.534 | 375.41 | 385.214 | 406.818 |
Total Common Shares Outstanding | 21.049 | 20.884 | 20.791 | 20.72 | 20.618 |
Capital Lease Obligations |
- Aastas
- Kvartalis
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Netotulu/algväärtus | -121.755 | -78.996 | -36.168 | 46.383 | 71.956 |
Raha majandustegevusest | -84.782 | -69.996 | 7.088 | 71.418 | 29.22 |
Raha majandustegevusest | 2.973 | 3.334 | 3.644 | 3.258 | 2.518 |
Deferred Taxes | 0 | 0.345 | 10.608 | -3.138 | 1.858 |
Mittelikviidsed varad | 27.211 | 19.009 | 16.104 | 13.424 | 14.675 |
Cash Taxes Paid | 0 | 0.032 | 0.105 | 12.672 | 26.088 |
Muutused tööjõus | 6.789 | -13.688 | 12.9 | 11.491 | -61.787 |
Tulu investeeringutelt | 54.897 | 36.991 | 19.83 | -86.664 | -35.402 |
Kapitalikulutused | -2.125 | -0.75 | -1.445 | -5.417 | -2.981 |
Muud rahavood investeeringutelt, kokku | 57.022 | 37.741 | 21.275 | -81.247 | -32.421 |
Rahavood investeeringutelt | 20.033 | 3.08 | 8.983 | 2.574 | 4.409 |
Aktsiate emiteerimine (tagasiost), neto | 21.262 | 3.614 | 10.481 | 6.848 | 6.244 |
Laenu väljastamine (kustutamine), neto | -0.086 | -0.079 | |||
Rahaline kogumuutus | -9.852 | -29.925 | 35.901 | -12.672 | -1.773 |
Rahavoogudesse investeerimine | -1.229 | -0.534 | -1.498 | -4.188 | -1.756 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -66.644 | -28.986 | -121.755 | -95.407 | -63.707 |
Cash From Operating Activities | -49.424 | -35.641 | -84.782 | -69.248 | -39.646 |
Cash From Operating Activities | 1.051 | 0.511 | 2.973 | 2.318 | 1.602 |
Non-Cash Items | 13.122 | 6.8 | 27.211 | 20.408 | 12.659 |
Changes in Working Capital | 3.047 | -13.966 | 6.789 | 3.433 | 9.8 |
Cash From Investing Activities | 80.334 | 33.569 | 54.897 | 26.666 | 10.446 |
Capital Expenditures | -5.539 | -3.156 | -2.125 | -0.688 | -0.437 |
Other Investing Cash Flow Items, Total | 85.873 | 36.725 | 57.022 | 27.354 | 10.883 |
Cash From Financing Activities | -1.726 | 0.301 | 20.033 | 17.103 | 12.983 |
Financing Cash Flow Items | -3.734 | -0.825 | -1.229 | -1.228 | -1.228 |
Issuance (Retirement) of Stock, Net | 2.008 | 1.126 | 21.262 | 18.331 | 14.211 |
Net Change in Cash | 29.184 | -1.771 | -9.852 | -25.479 | -16.217 |
Deferred Taxes | 0 | ||||
Cash Taxes Paid | 0 |
Investori nimi | Investori liik | Ringluse protsent | Hoitud osakud | Muutus osakutes | Hoidmise kuupäev | Hinnang käibele |
---|---|---|---|---|---|---|
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 15.6882 | 3303218 | 14720 | 2023-03-31 | LOW |
Armistice Capital LLC | Hedge Fund | 9.5557 | 2012000 | -66000 | 2023-03-31 | HIGH |
Farallon Capital Management, L.L.C. | Hedge Fund | 7.3615 | 1550000 | 0 | 2023-03-31 | MED |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 7.2826 | 1533376 | 14714 | 2023-03-31 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 5.7037 | 1200936 | -311256 | 2023-03-31 | LOW |
Braidwell LP | Hedge Fund | 4.9313 | 1038310 | 712472 | 2023-03-31 | HIGH |
Luly (Jay R) | Individual Investor | 3.4399 | 724285 | 0 | 2023-03-13 | LOW |
Northern Trust Global Investments | Investment Advisor | 3.159 | 665130 | -21685 | 2023-03-31 | LOW |
Krensavage Asset Management, LLC | Investment Advisor | 2.8653 | 603301 | 8483 | 2023-03-31 | LOW |
Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 2.5584 | 538689 | -4877 | 2023-03-31 | LOW |
Renaissance Technologies LLC | Hedge Fund | 2.0302 | 427464 | -45736 | 2023-03-31 | HIGH |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.8764 | 395076 | 16135 | 2023-03-31 | LOW |
Jacobs Levy Equity Management, Inc. | Investment Advisor/Hedge Fund | 1.7283 | 363909 | -2640 | 2023-03-31 | MED |
Or (Yat Sun) | Individual Investor | 1.6376 | 344802 | 0 | 2023-03-15 | LOW |
BlackRock Financial Management, Inc. | Investment Advisor/Hedge Fund | 1.4265 | 300354 | 13533 | 2023-03-31 | LOW |
Citadel Advisors LLC | Hedge Fund | 1.3819 | 290957 | 180891 | 2023-03-31 | HIGH |
Invesco Capital Management LLC | Investment Advisor | 1.3734 | 289177 | 195651 | 2023-03-31 | LOW |
Pictet Asset Management Ltd. | Investment Advisor/Hedge Fund | 1.2864 | 270853 | 197916 | 2023-03-31 | LOW |
UBS Asset Management (Switzerland) | Investment Advisor | 1.2735 | 268134 | -3432 | 2023-03-31 | LOW |
First Manhattan Co. LLC | Investment Advisor | 1.2509 | 263375 | 19657 | 2023-03-31 | LOW |
Miks valida Capital.com? Meie numbrid räägivad iseenda eest.
Capital.com Group535K+
Kauplejad
87K+
Igakuiste aktiivsete klientide arv
$113M+
Igakuine investeerimise maht
$64M+
Igakuiselt välja võetud
Kauplemiskalkulaator
Arvutage oma hüpoteetiline võit/kaotus, kui oleksite avanud CFD-tehingu ühel kindlal kuupäeval (valige kuupäev) ja sulgenud teisel kuupäeval (valige kuupäev).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Enanta Company profile
Ettevõttest Enanta
Enanta Pharmaceuticals, Inc. on biotehnoloogia ettevõte. Ettevõte tegeleb väikemolekulaarsete ravimite arendamisega viirusinfektsioonide ja maksahaiguste raviks. Ettevõttel on kliinilised kandidaadid haiguste sihtmärkide, sealhulgas respiratoorse süntsütsiaalviiruse (RSV), B-hepatiidi viiruse (HBV) ja mittealkohoolse steatohepatiidi (NASH) raviks. Ettevõte on avastanud glecapreviiri, proteaasi inhibiitori, mis on avastatud ja välja töötatud kroonilise C-hepatiidi viiruse (HCV) raviks. Glekapreviir on otsese toimega viirusevastane ravim (DAA), kombineeritud ravi HCV-infektsiooni raviks kaubanimede all: MAVYRET ja MAVIRET. Tema tootekandidaatide hulka kuuluvad ka EDP-514, EDP-305 ja EDP-938. Ettevõtte tütarettevõte on Enanta Pharmaceuticals Security Corporation.
Industry: | Biotechnology & Medical Research (NEC) |
500 Arsenal Street
WATERTOWN
MASSACHUSETTS 02472
US
Tuluaruanne
- Annual
- Quarterly
Teised on vaadanud veel
Kas otsite jätkuvalt vahendajat, keda saab usaldada?
Ühinege 535,000+ kauplejaga üle kogu maailma, kes valisid kauplemiseks veebisaidi Capital.com